Vaccine Market Trends, Size, Share, Analysis, 2024-2032 | IMARC Group


The latest report by IMARC Group, titled“ Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032 ,” offers a comprehensive analysis of the industry, which comprises insights on the global vaccine market research report . The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global vaccine market size reached US$ 54.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 124.5 Billion by 2032, exhibiting a growth rate (CAGR) of 9.6% during 2024-2032.

A vaccine is a biological preparation that stimulates the immune system to develop immunity to a specific disease, thereby protecting the individual from future infections. Manufactured through a rigorous process involving research, development, testing, and regulatory approval, vaccines typically contain weakened or inactivated forms of the disease-causing agent, fragments of the agent, or toxins produced by the agent. The importance of vaccines cannot be overstated, as they have been instrumental in preventing countless deaths and reducing the burden of infectious diseases worldwide. Their benefits extend beyond individual protection to the concept of herd immunity, where a sufficient proportion of a population is immunized, providing indirect protection to those who cannot be vaccinated due to age, health conditions, or other factors.

Request Free Sample Report:

Global Vaccine Market Trends and Drivers :

The global market is primarily driven by the increasing emphasis on preventative healthcare measures and immunization programs by governments and healthcare organizations worldwide. Additionally, continual advancements in vaccine technology, including the development of novel delivery systems and adjuvants, are expanding the market's potential. Moreover, the rising awareness among populations about the importance of vaccination in maintaining public health is further driving market growth.

Furthermore, strategic collaborations between pharmaceutical companies, research institutions, and governments to expedite vaccine development and distribution are shaping the market landscape. In line with this, the rise of vaccine awareness campaigns and advocacy efforts by healthcare professionals and non-governmental organizations (NGOs) is fostering a positive perception of vaccination among the public, leading to higher vaccination rates and market expansion.

By the IMARC Group, Some of the Top Competitive Landscape Operating in the Industry are Given Below:

  • Abbott Laboratories (NYSE: ABT)
  • Astellas Pharma Inc. (OTCMKTS: ALPMY)
  • AstraZeneca Plc (NASDAQ: AZN)
  • Bharat Biotech International Limited
  • Bavarian Nordic A/S (OTCMKTS: BVNRY)
  • CSL Limited (OTCMKTS: CSLLY)
  • Daiichi Sankyo Company, Limited (OTCMKTS: DSNKY)
  • Emergent BioSolutions Inc. (NYSE: EBS)
  • GlaxoSmithKline Plc (NYSE: GSK)
  • Inovio Pharmaceuticals Inc. (NASDAQ: INO)
  • Johnson & Johnson, Inc. (NYSE: JNJ)
  • Merck & Co. Inc. (NYSE: MRK)
  • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
  • Novavax Inc. (NASDAQ: NVAX)
  • Panacea Biotec Ltd. (NSE: PANACEABIO)
  • Pfizer Inc. (NYSE: PFE)
  • Sanofi Pasteur SA (Sanofi SA) (NASDAQ: SNY)
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited (NYSE: TAK)

Key Market Segmentation:

Breakup by Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Others

Breakup by Patient Type:

  • Paediatric
  • Adult

Breakup by Indication:

  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis (DPT)
    • Tuberculosis
    • Haemophilus Influenzae (Hib)
    • Typhoid
    • Others
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus (HPV)
    • Measles/Mumps/Rubella (MMR)
    • Rotavirus
    • Herpes Zoster
    • Varicella
    • Japanese Encephalitis
    • Rubella
    • Polio
    • Rabies
    • Dengue
    • Others

Breakup by Route of Administration:

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

Breakup by Product Type:

  • Multivalent Vaccine
  • Monovalent Vaccine

Breakup by Treatment Type:

  • Preventive Vaccine
  • Therapeutic Vaccine

Breakup by End User:

  • Hospitals
  • Clinics
  • Vaccination Centres
  • Academic and Research Institutes
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the Report:

  • Market Performance (2018-2023)
  • Market Outlook ( 2024-2032 )
  • COVID-19 Impact on the Market
  • Porter's Five Forces Analysis
  • Historical, Current and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US


30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.